国家: 美国
语言: 英文
来源: NLM (National Library of Medicine)
AZATHIOPRINE (UNII: MRK240IY2L) (AZATHIOPRINE - UNII:MRK240IY2L)
Mylan Institutional Inc.
AZATHIOPRINE
AZATHIOPRINE 50 mg
ORAL
PRESCRIPTION DRUG
Azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. Azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. Experience with over 16,000 transplants shows a 5-year patient survival of 35% to 55%, but this is dependent on donor, match for HLA antigens, anti-donor or anti-B-cell alloantigen antibody, and other variables. The effect of azathioprine tablets on these variables has not been tested in controlled trials. Azathioprine tablets are indicated for the treatment of active rheumatoid arthritis (RA) to reduce signs and symptoms. Aspirin, non-steroidal anti-inflammatory drugs and/or low dose glucocorticoids may be continued during treatment with azathioprine tablets. The combined use of azathioprine tablets with disease modifying anti-rheumatic drugs (DMARDs) has not been studied for either added be
Azathioprine Tablets, USP are available containing 50 mg of azathioprine, USP. The 50 mg tablets are yellow, round, scored tablets debossed with A to the left of the score and Z to the right of the score on one side of the tablet and blank on the other side. They are available as follows: NDC 51079-620-06 – Unit dose blister packages of 50 (5 cards of 10 tablets each). Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Store in a dry place and protect from light.
Abbreviated New Drug Application
AZATHIOPRINE- AZATHIOPRINE TABLET MYLAN INSTITUTIONAL INC. ---------- WARNING - MALIGNANCY CHRONIC IMMUNOSUPPRESSION WITH AZATHIOPRINE, A PURINE ANTIMETABOLITE INCREASES _RISK OF_ _MALIGNANCY _IN HUMANS. REPORTS OF MALIGNANCY INCLUDE POST-TRANSPLANT LYMPHOMA AND HEPATOSPLENIC T-CELL LYMPHOMA (HSTCL) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. PHYSICIANS USING THIS DRUG SHOULD BE VERY FAMILIAR WITH THIS RISK AS WELL AS WITH THE MUTAGENIC POTENTIAL TO BOTH MEN AND WOMEN AND WITH POSSIBLE HEMATOLOGIC TOXICITIES. PHYSICIANS SHOULD INFORM PATIENTS OF THE RISK OF MALIGNANCY WITH AZATHIOPRINE TABLETS. SEE WARNINGS. DESCRIPTION Azathioprine, an immunosuppressive antimetabolite, is available in tablet form for oral administration. Each scored tablet contains 50 mg azathioprine, USP and the inactive ingredients corn starch, lactose monohydrate, magnesium stearate, povidone and stearic acid. Azathioprine is chemically 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine. The structural formula of azathioprine is: It is an imidazolyl derivative of 6-mercaptopurine and many of its biological effects are similar to those of the parent compound. Azathioprine is insoluble in water, but may be dissolved with addition of one molar equivalent of alkali. Azathioprine is stable in solution at neutral or acid pH but hydrolysis to mercaptopurine occurs in excess sodium hydroxide (0.1N), especially on warming. Conversion to mercaptopurine also occurs in the presence of sulfhydryl compounds such as cysteine, glutathione, and hydrogen sulfide. CLINICAL PHARMACOLOGY Azathioprine is well absorbed following oral administration. Maximum serum radioactivity occurs at 1 to 2 hours after oral S-azathioprine and decays with a half-life of 5 hours. This is not an estimate of the half-life of azathioprine itself, but is the decay rate for all S-containing metabolites of the drug. Because of extensive metabolism, only a fraction of the radioactivity is present as azathioprine. Usual doses produce blood levels of azathioprine, and of mercaptopurine derived 阅读完整的文件